Expiration of Biosource Royalty Obligation Sample Clauses

Expiration of Biosource Royalty Obligation. Biosource's obligation to pay royalties under this Agreement to TDCC in respect of a Biosource Product shall cease as of: (i) if manufacture, sale or use of the Biosource Product is not covered by Patent Rights as provided in part (ii) of this Section 6.5.6, on the last day of a calendar quarter in which falls the tenth (10th) anniversary of the First Commercial Sale of any Biosource Product for which royalties are payable under Section 6.5.2, directly or indirectly, by Biosource or one of its Affiliates anywhere in the world; or (ii) if the manufacture, sale or use of the Biosource Product is covered by Patent Rights in the country where such activity occurs, which claim inventions discovered in the course of Research Collaboration or in the exercise of post-Research Collaboration rights granted to Biosource in Sections 3.5 hereof, upon the occurrence of any of the following: (a) the expiration of the last Valid Claims of the aforementioned Patent Rights covering the Biosource Product in that country that can reasonably be expected to deliver Agricultural Value-Added or Non-Agricultural Value-Added to Biosource, (b) when the remaining Valid Claims of the aforementioned Patent Rights covering the Biosource Product in that country will no longer deliver significant Agricultural Value-Added or Non-Agricultural Value-Added to Biosource, or (c) when the remaining Valid Claims of the aforementioned Patent Rights in that country are likely to be held invalid or unenforceable.
Sample 1Sample 2
AutoNDA by SimpleDocs

Related to Expiration of Biosource Royalty Obligation

  • Duration of Royalty Obligations The royalty obligations of Licensee as to each Product shall terminate on a country-by-country and product-by-product basis concurrently with the expiration of:

  • Royalty Obligations Part 2.7(e) of the Disclosure Schedule contains a complete and accurate list and summary of all royalties, fees, commissions, and other amounts payable by the Seller to any Person (other than sales commissions paid to employees according to the Seller’s standard commissions plan) upon or for the sale, or distribution of any Seller Product or the use of any Seller IP.

  • Sublicense Fees Licensee will pay Sublicense Fees indicated in Section 3.1(e) of the Patent & Technology License Agreement on or before the Quarterly Payment Deadline for the Contract Quarter.

  • Payment of Royalties To the best of Seller’s knowledge, all royalties and in-lieu royalties with respect to the Assets which accrued or are attributable to the period prior to the Effective Time have been properly and fully paid, or are included within the suspense amounts being conveyed to Buyer pursuant to Section 11.4.

  • Know-How Royalty Notwithstanding the provisions of Section 5.4.1(a), in countries where the sale of Product by Merck or its Related Parties would not infringe a Valid Patent Claim, Merck shall pay royalty rates that shall be set at [***] of the applicable royalty rate determined according to Section 5.4.1(a). Such royalties shall be calculated after first calculating royalties under Section 5.4.1(a).

  • Payment of Royalty If the Optionor and Optionee have formed the Joint Venture under Article 4.1 hereof, then until either the Optionee or Optionor ceases to have any interest in the Joint Venture and the Property, the Optionee and Optionor shall pay their proportionate shares(based on their respective undivided interests in the Joint Venture) of any royalty payable to any governmental body.

  • Obligation to Pay Royalties A royalty is due Stanford under this Agreement for any activity conducted under the licenses granted. For convenience’s sake, the amount of that royalty is calculated using Net Sales. Nonetheless, if certain Licensed Products are made, used, imported, or offered for sale before the date this Agreement terminates, and those Licensed Products are sold after the termination date, ImmuMetrix will pay Stanford an earned royalty for its exercise of rights based on the Net Sales of those Licensed Products.

  • Minimum Royalty At the beginning of each calendar year during the term of this Agreement, beginning January 1, 2016, Company shall pay to Medical School a minimum royalty of {***}. If the actual royalty payments to Medical School in any calendar year are less than the minimum royalty payment required for that year, Company shall have the right to pay Medical School the difference between the actual royalty payment and the minimum royalty payment in full satisfaction of its obligations under this Section, provided such minimum payment is made to Medical School within sixty (60) days after the conclusion of the calendar year. Waiver of any minimum royalty payment by Medical School shall not be construed as a waiver of any subsequent minimum royalty payment. If Company fails to make any minimum royalty payment within the sixty-day period, such failure shall constitute a material breach of its obligations under this Agreement, and Medical School shall have the right to terminate this Agreement in accordance with Section 8.3.

  • Minimum Royalties If royalties paid to Licensor do not reach the minimum royalty amounts stated in Section 3.3 of the Patent & Technology License Agreement for the specified periods, Licensee will pay Licensor on or before the Quarterly Payment Deadline for the last Contract Quarter in the stated period an additional amount equal to the difference between the stated minimum royalty amount and the actual royalties paid to Licensor.

  • Liability for Specific Obligations The Administrator will be liable only for its specific obligations under this Agreement. All other liability is expressly waived and released as a condition of, and consideration for, the execution of this Agreement by the Administrator. The Administrator will be liable for its willful misconduct, bad faith or negligence in performing its obligations under this Agreement.

Time is Money Join Law Insider Premium to draft better contracts faster.